Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: Justification for the use of statins in prevention: An intervention trial evaluating rosuvastatin (JUPITER)

Circulation: Cardiovascular Quality and Outcomes

Volumn 2, Issue 6, 2009, Pages 616-623

  Ridker, Paul M ^a   MacFadyen, Jean G ^a,c   Fonseca, Francisco A H ^b   Genest, Jacques ^a   Gotto, Antonio M ^d   Kastelein, John J P ^e   Koenig, Wolfgang ^f   Libby, Peter ^a   Lorenzatti, Alberto J ^g   Nordestgaard, Børge G ^h   Shepherd, James ⁱ   Willerson, James T ^j   Glynn, Robert J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f UNIVERSITY OF ULM   (Germany)

^g HOSPITAL PRIVADO   (Argentina)

^h GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

ⁱ UNIVERSITY OF GLASGOW   (United Kingdom)

^j ST LUKE S EPISCOPAL HOSPITAL   (United States)

more..

Author keywords

Epidemiology; Outcomes research; Prevention and control; Primary prevention; Risk factors; Statins

Indexed keywords

C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; RISK REDUCTION; SENSITIVITY ANALYSIS; STROKE; AGE; BIOASSAY; BLOOD; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; METABOLIC SYNDROME X; RACE; RISK FACTOR; STATISTICS;

AGE FACTORS; BODY MASS INDEX; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; CONTINENTAL POPULATION GROUPS; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; FLUOROBENZENES; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; METABOLIC SYNDROME X; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PRIMARY PREVENTION; PYRIMIDINES; RISK FACTORS; STROKE; SULFONAMIDES;

EID: 77649228312     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.109.848473     Document Type: Article

References (23)

1. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gottto AM, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. For the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
2. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gottto AM, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. On behalf of the JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet. 2009;373:175-182.
3. Glynn RJ, Danielson E, Fonseca FAH, Genest J, Gottto AM, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Ridker PM. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009;360:1851-1861.
4. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999;319:1492-1495.
5. Lubsen J, Hoes A, Grobbee D. Implications of trial results: The potentially misleading notions of number needed to treat and average duration of life gained. Lancet. 2000;356:1757-1759.
6. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279: 1615-1622.
7. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
8. Superko HR, King S. Lipid management to reduce cardiovascular risk: A new strategy is required. Circulation. 2008;117:560-568.
9. Kumana CR, Cheung BMY, Lauder IJ. Gauging the impact of statins using number needed to treat. JAMA. 1999;282:1899-1901.
10. Sacks FM, Pfeffer MA, Moye L, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. The Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-1009.
11. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
12. Pearce KA, Furberg CD, Psaty BM, Kirk J. Cost-minimization and the number needed to treat in umcomplicated hypertension. Am J Hypertens. 1998;11:618-629.
13. Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, Volmink J. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2007;(1):CD002003.
14. Steering Committee of the Physicians' Health Study Research group. Final report on the aspirin component of the ongoing Physician's Health Study. N Engl J Med. 1989;321:129-135.
15. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-1304.
16. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: A sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295:306-313.
17. Ridker PM, Fonseca FAH, Genest J, Gottto AM, Kastelein JJP, Khurmi NS, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, on behalf of the JUPITER Trial Study Group. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol. 2007;100: 1659-1664.
18. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment.NEngl J Med. 1988;318:1728-1733.
19. Cook RJ, Sackett DL. The number needed to treat: A clinically useful measure of treatment effect. BMJ. 1995;310:452-454.
20. Halvorsen PA, Selmer R, Kristiansen IS. Different ways to describe the benefits of risk-reducing treatments. A randomized trial. Ann Int Med. 2007;146:848-856.
21. Sydes MR, Parmar MKB. Interim monitoring of efficacy data is important and appropriaate. J Clin Epi. 2008;61:203-204.
22. Goodman SN. Stopping at nothing? Some dilemmas of data monitoring in clinical trials. Ann Intern Med. 2007;146:882-887.
23. Ridker PM, Rifai N, Clearfield M, downs JR, Weis SE, Miles JS, Gotto AM. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959-1965.